{"id":"standard-dose-levetiracetam","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-15","effect":"Asthenia/fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Behavioral/mood changes (irritability, aggression)"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes, thereby decreasing seizure susceptibility. The exact mechanism remains incompletely understood, but SV2A binding is considered the primary molecular action responsible for its antiepileptic effects.","oneSentence":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:09.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Myoclonic seizures in juvenile myoclonic epilepsy (adjunctive therapy)"},{"name":"Primary generalized tonic-clonic seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06442748","phase":"PHASE3","title":"Short Versus Long-term Levetiracetam in Brain Tumors","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-07-04","conditions":"Seizures, Brain Tumors, Antiepileptics","enrollment":604},{"nctId":"NCT07401433","phase":"NA","title":"Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.","status":"COMPLETED","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2024-04-08","conditions":"Neonatal Seizures","enrollment":260},{"nctId":"NCT07284498","phase":"PHASE4","title":"Treatment of Seizures in Neonate With HIE","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-01","conditions":"Neonatal Seizures, HIE - Hypoxic - Ischemic Encephalopathy","enrollment":66},{"nctId":"NCT04833907","phase":"PHASE1, PHASE2","title":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Myrtelle Inc.","startDate":"2021-04-01","conditions":"Canavan Disease","enrollment":24},{"nctId":"NCT05610085","phase":"PHASE2","title":"A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-03-24","conditions":"Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy","enrollment":133},{"nctId":"NCT07220902","phase":"PHASE3","title":"Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure","status":"NOT_YET_RECRUITING","sponsor":"Nebraska Methodist Health System","startDate":"2026-01-01","conditions":"Severe Preeclampsia, Eclampsia Preeclampsia","enrollment":1240},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT06549426","phase":"NA","title":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","status":"RECRUITING","sponsor":"University of Twente","startDate":"2025-04-10","conditions":"Coma, Electrographic Status Epilepticus","enrollment":150},{"nctId":"NCT05263674","phase":"PHASE3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":"Non-Convulsive Status Epilepticus","enrollment":140},{"nctId":"NCT04497142","phase":"PHASE1, PHASE2","title":"Effect of Perampanel on Peritumoral Hyperexcitability in HGG","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-05","conditions":"Glioma, Malignant, Surgery, Seizures","enrollment":12},{"nctId":"NCT05450822","phase":"","title":"Precision Medicine in the Treatment of Epilepsy","status":"RECRUITING","sponsor":"Gitte Moos Knudsen","startDate":"2022-02-18","conditions":"Epilepsy","enrollment":550},{"nctId":"NCT03325439","phase":"PHASE3","title":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-05-07","conditions":"Electroencephalographic Neonatal Seizures","enrollment":9},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT02056236","phase":"NA","title":"TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation","status":"COMPLETED","sponsor":"University of Twente","startDate":"2014-04","conditions":"Cardiac Arrest, Anoxic Encephalopathy, Status Epilepticus","enrollment":172},{"nctId":"NCT01464359","phase":"PHASE2","title":"T-Cell Depleted Double UCB for Refractory AML","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10","conditions":"Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia","enrollment":3},{"nctId":"NCT02726867","phase":"PHASE3","title":"Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus","status":"WITHDRAWN","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","startDate":"2014-02","conditions":"Epilepsy, Status Epilepticus","enrollment":""},{"nctId":"NCT01660672","phase":"PHASE1, PHASE2","title":"Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2013-01","conditions":"Seizure, Epilepsy, Cerebral Malaria","enrollment":7},{"nctId":"NCT01982812","phase":"PHASE2","title":"A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-01","conditions":"Seizure, Epilepsy, Cerebral Malaria","enrollment":44},{"nctId":"NCT01463033","phase":"PHASE2","title":"Levetiracetam to Prevent Post-Traumatic Epilepsy","status":"COMPLETED","sponsor":"Pavel Klein","startDate":"2005-04","conditions":"Epilepsy, Post-traumatic Epilepsy","enrollment":126},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT00175903","phase":"PHASE3","title":"Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-02","conditions":"Epilepsy","enrollment":1701}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard levetiracetam"],"phase":"marketed","status":"active","brandName":"Standard dose levetiracetam","genericName":"Standard dose levetiracetam","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release. Used for Partial-onset seizures (adjunctive therapy), Myoclonic seizures in juvenile myoclonic epilepsy (adjunctive therapy), Primary generalized tonic-clonic seizures (adjunctive therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}